Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered biologics.

Mayo Clinic researchers have identified interleukin-23 receptor (IL-23R) as a significant biomarker of cellular senescence and aging in both mice and humans. Experiments show that IL-23R levels in ...

has announced encouraging results from its Phase 3 investigational study of icotrokinra (JNJ-2113), a groundbreaking oral peptide designed to selectively block the IL-23 receptor. The drug showed ...

JNJ-2113 is an oral IL-23R antagonist peptide that binds to the IL-23 receptor. The IL-23/IL-23R signalling pathway plays a vital role in the pathogenesis of plaque psoriasis and other immune ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...

One group reported that an uncommon variant of the gene encoding the IL-23 receptor (IL-23R) confers strong protection against Crohn disease 5. Another set of researchers examined patients with ...

By blocking its interaction with the IL-23 receptor, mirikizumab inhibits the release of pro-inflammatory cytokines and chemokines. The approval was based on data from the randomized, double-blind ...